Karine Lélu, et al. Journal of Hepatology, April 2015, Volume 62, Supplement 2, Page S205 – Download the article Publication
Catégorie : Publication
TG1050, a Novel Immunotherapeutic to Treat Chronic Hepatitis B, can Control HBsAg and Provoke HBsAg Seroconversion in HBV-Persistent Mouse Models
Karine Lélu, et al. EASL Liver Congress 2015, Vienna-23th April 2015 Download the poster here Poster Presentation
Immune checkpoint inhibitors enhance benefits of modified vaccinia virus Ankara to improve survival in preclinical models of cancer
Poster TG4010-AACR 2015-KR Karola Rittner, et al. AACR Annual Meeting, Philadelphia, PA, USA, 18-22 April 2015, Abst. 2497 Download the poster here Poster Presentation
The MVA viral platform for the treatment of cancer and chronic infectious diseases: Clinical experience from four randomized controlled phase II studies
Poster MVA VIRAL PLATFORM-AACR 2015-JML Jean-Marc Limacher, et al. AACR Annual Meeting, Philadelphia, PA, USA, 18-22 April 2015, Abst. 2498. Download the poster here Poster Presentation
Viral hepatitis: HBV cure—can we pin our hopes on immunotherapy ?
Hung-Chih Yang, et al. Nature Reviews Gastroenterology & Hepatology (2015) doi:10.1038/nrgastro.2015.8 – Download the article Publication
TG1050, an immunotherapeutic to treat chronic hepatitis B, induces robust T cells and exerts an antiviral effect in HBV-persistent mice.
Martin P, Dubois, et al. Gut. 2014 Nov 26, doi: 10.1136/gutjnl-2014-308041 – Download the article Publication
TG4010 Immunotherapy Combined with First-line Therapy in Advanced Non- Small Cell Lung Cancer (NSCLC). Phase 2b Results of the TIME Study
Elisabeth Quoix, et al. Journal for Immunotherapy of Cancer, 2014, 2 (suppl. 3), O12 – Download the article Publication
TIME: A Phase 2b/3 Evaluating TG4010 in Combination with First-line Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC). Phase 2b results.
ESMO 2014-Poster TG4010 TIME Ph 2b Elisabeth Quoix, et al. ESMO 2014 Congress, Madrid, Spain, 26-30 September 2014, Abst. 5152 Download the poster here Poster Presentation
Efficacy of immunotherapy with TG4040, Peg-interferon, and ribavirin in A phase 2 study of patients with chronic HCV infection.
Adrian Di Bisceglie, et al. Gastroenterology, 2014; Mar 18 – Download the article Publication
Comparative analysis of immunization schedules using a novel adenovirus – based immunotherapeutic targeting hepatitis B in naïve and tolerant mouse models.
Houda Boukhebza, et al. Vaccine. 2014, 32(26):3256-63. – Download the article Publication